4820 Richard Road SW
Suite 300
Calgary, AB T3E 6L1
Canada
https://www.resverlogix.com
Sector(s):Â Healthcare
Industry:Â Biotechnology
Full Time Employees:Â 22
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Donald J. McCaffrey | Co-Founder, Chairman, Pres, CEO & Sec. | 505.2k | N/A | N/A |
Mr. Aaron Bradley Cann C.A., CPA, CA, CPA, CBV | Chief Financial Officer | 281.8k | N/A | N/A |
Dr. Michael Sweeney M.D. | Sr. VP of Clinical Devel. | 523.4k | N/A | 1961 |
Dr. Ewelina Kulikowski Ph.D. | Sr. VP of Scientific Devel. | 250k | N/A | N/A |
Dr. Norman C.W. Wong B.Sc (Hon), B.Sc., FRCP(C), FRCPC, M.D., M.Sc, M.S | Co-Founder, Chief Scientific Officer & Chairman of the Scientific Advisory Board | N/A | N/A | N/A |
Sarah Zapotichny | Director of Investor Relations & Corp. Communications | N/A | N/A | N/A |
Dr. Jan O. Johansson M.D., Ph.D. | Sr. VP of Medical Affairs | N/A | N/A | N/A |
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.
Resverlogix Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.